News | September 17, 2007

FDA Clears High-Definition Collimator for IMRS

September 18, 2007 – Varian Medical Systems has received FDA 510(k) clearance for a new high-definition multileaf collimator (MLC), the HD120 MLC, an ultra-fine beam shaping device for radiosurgery, optimized for targeting tumors and other abnormalities with high-dose stereotactic radiotherapy and radiosurgery.

The new HD120 MLC multileaf collimator enables clinicians to deliver extremely precise radiosurgical treatments, including intensity-modulated radiosurgery (IMRS), and will be included with the new Novalis Tx radiosurgery system that Varian is teaming up with BrainLab to offer.

The Novalis Tx offers a noninvasive alternative to conventional surgery for a wide spectrum of conditions, including benign and malignant tumors, metastatic cancer and neurological conditions like arteriovenous malformations, trigeminal neuralgia and acoustic schwannoma.

Varian’s new HD120 MLC multileaf collimator doubles the resolution of our best MLC, and is designed carrying out delicate intensity-modulated radiosurgeries near critical structures like the optic chiasm, brain stem or spinal cord.

The HD120 MLC has reduced the width of the central leaves from 5 millimeters wide to 2.5 millimeters, theoretically increasing the beam-shaping precision by 100 percent.

The new collimator also steeper dose fall-off gradient, so that the amount of dose delivered decreases rapidly outside the targeted area, protecting healthy tissues more effectively than is possible with earlier beam shaping devices.

For more information: www.varian.com

Related Content

SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
RaySearch Releases New Version of RayCare OIS
Technology | Oncology Information Management Systems (OIMS) | July 13, 2018
RaySearch has released RayCare 2A, the latest version of its flagship oncology information system (OIS). RayCare is...
Lack of Insurance Coverage Delaying Proton Therapy Clinical Trials
News | Proton Therapy | July 12, 2018
Randomized clinical trials are the gold standard of cancer research and can shed light on whether innovative, new...
Bruce Power Joins Forces With ITM to Supply Lutetium-177 for Cancer Therapy
News | Radiation Therapy | July 11, 2018
Canadian nuclear power company Bruce Power and German-based Isotope Technologies Garching (ITG) signed an agreement to...
MedStar Georgetown University Hospital Now Clinical With RayStation and Hyperscan
News | Treatment Planning | July 05, 2018
MedStar Georgetown University Hospital in Washington D.C., has begun patient treatments using the RayStation treatment...
Northern Centre for Cancer Care (NCCC)

Northern Centre for Cancer Care (NCCC).

Sponsored Content | Case Study | Radiation Therapy | July 05, 2018
Established in 2009, Northern Centre for Cancer Care (NCCC) is the largest center of its kind in the north of England....
Researcher Investigates Eliminating Radiation for HER2-Positive Breast Cancer
News | Radiation Therapy | July 02, 2018
Researchers at The University of Kansas Cancer Center have launched a clinical trial that eliminates radiation from the...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
Overlay Init